My Medical Record supported self-management and remote monitoring

Regular Off Off

My Medical Record is a free and secure website where you can access information about your post cancer treatment follow-up. It is currently available to a limited number of cancer specialties at North Bristol NHS Trust.
The website enables you to self-manage your follow-up care from home, and allow your cancer support team to remotely monitor your test results and provide support. In many cases this will reduce the number of outpatient appointments you need to attend at the hospital. You will be invited by a member of your cancer support team to access My Medical Record at an appropriate point in your pathway. 

How to sign up

When appropriate, your Consultant or Clinical Nurse Specialist will refer you to have your follow-up remotely monitored by the cancer support team. You will then be introduced to the My Medical Record website and offered access.

To register for My Medical Record you will need to provide an email address and telephone number.

If you are already registered on My Medical Record, please visit My medical record (uhs.nhs.uk).

My Medical Record offers:

  • Information and support to help you to self-manage during your follow up.
  • A plan for the ongoing tests you need.
  • The ability for you and your cancer support team to monitor your test results remotely.
  • Secure online access to letters associated with your follow-up plan.
  • A way to securely message your cancer support team.
  • Access from any web-enabled device, at any time.
  • Access to reliable information about your condition, such as websites, apps, videos, leaflets and support groups.

What if I do not have access to the internet?

If you do not have internet access or an email address, you may decide to allow a family member or friend to help you access the system or log in on your behalf. You must get their consent to do this as we will store their email address and telephone number with your details.

Looking after your password

The information in My Medical Record is confidential and personal to you. You should protect your access details and password in the same way you would for other online services.

My Medical Record is owned and operated by University Hospital Southampton NHS Foundation Trust and is licensed for use by NBT.

© North Bristol NHS Trust. This edition published February 2024. Review due February 2027. NBT003332. 

Analytes

Regular Off Off

Benzylpenicilin (Penicillin G)

Isoniazid (+ N-Acetyl-Isoniazid)

Sulphamethoxazole in (Co-trimoxazole)

Trimethoprim in (Co-trimoxazole)

Antimicrobial Reference Laboratory Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

For General Enquiries and Results:

Telephone: 0117 4146269 or 0117 4146220
For Clinical Advice: 07802 720900
Fax: 0117 4146282
Email: arlenquiries@nbt.nhs.uk

Laboratory Hours

Monday to Friday 9am - 5.15pm, Saturday 9am - 12 noon

Consent and use of information

Regular Off Off

Consent

It is the responsibility of the responsible clinician to obtain consent for testing and storage. Our laboratories assume this has been done upon receipt of the sample and do not routinely check consent has been obtained.

Receipt of the sample and request form establishes an agreement to perform testing.

The following must be clearly stated on the referral form:-

Test required
Clinical details
Relevant family history
Mother’s details for prenatal testing requests

Where specific, informed consent is required for testing, this will be prompted on the request form. This is particularly appropriate for testing under the Human Tissue Act.

Further information on consent can be found in the following webpages:

Use of information

Pathology complies with the North Bristol NHS Trust policies to safeguard patient infomation Information Governance | North Bristol NHS Trust (nbt.nhs.uk).

Where there is a requirement to share information with a third party (e.g. regulatory or compliance body, or for monitoring of quality standards) information, comprising minimum data sets, will be only be shared once it has been fully anonymised. 

Gastroenterology Current Research

Regular Off Off Gastroenterology - Current Research

Gastroenterology research taking place at North Bristol NHS Trust

Please speak to the person treating you to see if there is a research study that may be able to help you.

Current Studies:

UK-PSC (A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis)

Primary Sclerosing Cholangitis (PSC), a condition characterised by progressive inflammation, obstruction and fibrosis of the intra- and extra-hepatic bile ducts of the liver, presents typically in the fourth or fifth decades leading often to cirrhosis, end stage liver disease and a need for liver transplantation. 

The PSC Genetics Study began in 2008, with the aim of sourcing DNA from over 3000 patients with Primary Sclerosing Cholangitis. To date over 1800 patients have participated in the study. This is a significant step towards our goal of identifying genes of potential significance in the pathogenesis of this condition.

Chief Investigator – Dr Gideon Hirschfield 

Principle Investigator - Dr Robert Przemioslo

R&I no: 2145 

PBC Genetics Study (Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis)

The PBC Genetics Study is a national effort to establish a PBC DNA collection consisting of DNA samples from approximately 5000 patients with PBC. The DNA collection has already been used for a genome-wide association study (GWAS) of PBC. The next major analysis will be a genome wide association study of response to Ursodeoxycholic acid (UDCA).

Chief Investigator - Dr Richard Sandford

Principle Investigator – Dr Robert Przemioslo

R&I no: 2030

Promise

The The Promise study is: A PROspective randomised double-blind parallel group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve the primary outcomE (first hospitalisation due to infection) in patients with cirrhosis over 24 months.

End-stage chronic liver disease, known as cirrhosis (irreversible scarring of the liver), is the third biggest cause of mortality and loss of working life in the UK. The human body contains trillions of bacteria, but people with cirrhosis have an increased number of ‘bad’ bacteria in the bowel which makes them highly susceptible to a host of infections. Over-prescribing antibiotics means they are becoming less effective to treat these infections, and the bowel can become infected with ‘super-bugs’. Replacing the unfriendly bowel bacteria in patients with cirrhosis with healthy bacteria donated from healthy volunteers (Faecal Microbiota Transplantation) could be highly beneficial and reduce antibiotic usage.

Project Details
Chief Investigator - Deborah Shawcross
Local PI – Dr Zeino Zeino 
R&D 5230

 

Reduce-2

Palliative Long-term Abdominal Drains Versus Repeated Drainage in Untreatable Ascites Due to Advanced Cirrhosis: A Randomised Controlled Trial (REDUCe 2 Study)

Our aim is to see if palliative long-term abdominal drains (LTADs) result in better quality of life in patients with fluid in the belly due to liver scarring (cirrhosis), compared with current standard of care. The liver can be damaged by excessive alcohol and viral infections. If liver damage continues this scarring leads to permanent damage. It causes a painful buildup of fluid in the abdomen (ascites). Drugs can treat this, but may stop working, leading to untreatable ascites. A liver transplant is then the best option. However, many do not receive a transplant due to concerns about their alcohol use or lack of donors. Life expectancy is on average six months and palliative care is needed. Current palliative care for untreatable ascites involves coming into hospital for 1-2 days, putting a thin tube into the abdomen for a few hours and draining the fluid. This reduces pain from ascites. However, as the ascites builds up quickly, hospital visits are needed every 10-14 days. For people with untreatable ascites due to cancer, palliative care involves placing another tube, an LTAD, into their abdomen. This tube is fitted in hospital but stays in place for months. Nurses/carers then drain smaller amounts of fluid regularly in the community. LTADs avoid frequent hospital visits and can improve quality of life. LTADs are not routinely offered to people with cirrhosis. We conducted a feasibility study where half the participants received LTADs and half continued with standard hospital drainage. The study went well, with no major issues. We now need a larger study to understand the risks/benefits of palliative LTADs in people with cirrhosis. In this larger study we will measure quality of life for both the participants and their carers. The study has been designed with help of the patients/caregivers who are part of the research team.

Chief Investigator – Prof Sumita Verma
Local PI – Dr Ankur Srivastava 
R&D - 5300

Boppp

Beta Blockers or placebo for primary prophylaxis of oesophageal varices (BOPPP Trial). A blinded, multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial

Cirrhosis or liver scarring is an important healthcare problem in the United Kingdom. There are 60,000 patients living with this disease and about 11,000 people die every year due to complications of cirrhosis. Bleeding from the oesophagus or stomach is one of these complications. Cirrhosis causes pressure changes inside the abdomen and swelling of veins in the oesophagus (called “varices”) which can cause fatal bleeding. Research has proven that large varices can be treated with beta-blockers (a type of anti-hypertensive medication) to reduce the pressure in the veins. The management of small varices is still uncertain. This study aims to discover if beta blockers can be used in this setting. We hypothesize that beta blockers will reduce the risk of bleeding from small varices from 20% to 10% over a period of 3 years, resulting in significant cost savings to the NHS from better patient outcomes. The study will be opened in approximately 25 centres nationally. Patients with small volume varices, identified by routine endoscopy, will be randomised to receive either beta-blockers or a placebo. They will be followed up 6 monthly for a period of 3 years. We will assess for complications of cirrhosis (including bleeding) and medicine related side effects. The varices will be monitored annually by endoscope for the duration of the study. General practitioners will be involved in monitoring patients and adjusting doses. As part of our analysis we will assess the impact of treatment on mortality and quality of life using a combined measure, the Quality Adjusted Life-Year (QALY). We will use a mathematical prediction model to estimate the impact of treatment on costs, mortality and quality of life over a patient’s lifetime; identifying if any increased costs are justified by better outcomes for patients and represent good value for money for the NHS budget.

Chief Investigator – Vishal Patel
Local PI – Dr Zeino Zeino 
R&D - 4499

Static

STopping Aminosalicylate Therapy in Inactive Crohn’s Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial

Aminosalicylate (5-ASA) agents have proven effective for inducing and maintaining remission in mild to moderate ulcerative colitis (UC) and thus are commonly used as first-line agents for patients with Crohn's disease (CD) in remission. However, there is uncertainty regarding their effectiveness for CD. In this open-label (where both the researchers and participants know which treatment is being administered), randomized study, participants with CD in remission will be allocated to either continue their 5-ASA therapy or withdraw their 5-ASA. The purpose is to investigate if withdrawal of 5-ASA therapy is not unacceptably less effective than continuing on 5-ASA in maintaining CD remission over a 24-month period. There will be a 2 year follow up period to see if participants develop any flares or complications of their CD, to monitor their quality of life and assess the impact on the cost associated with their assigned treatment. The results of the study may help to improve evidence based treatment guidelines and the approach to patient care. Participants will be randomly assigned by a computer to one of two groups: 1. Group 1: Continuation of 5-ASA treatment 2. Group 2: Discontinuation of 5-ASA treatment At the end of the study, half of the participants will be in Group 1 and half of the participants in Group 2. After participants have been assigned to one of these two study groups, they will continue in that group for the duration of their time in the study. Approximately 1580 participants will be taking part in this study. Participants will be asked to attend hospital visits for a total of 5 times over a two-year period, where they will undergo the following procedures at most or all study visits: Blood taking, Physical Exam(only at first visit), vital signs, medication review, side effects review, urine sample, questionnaires and stool samples.

Chief investigator – Dr Gordon Moran
Local PI – Dr Melanie Lockett 
R&D – 4472

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

Gastroenterology
R&I Gastroenterology.jpg

Ciclosporin

Regular Off Off

Introduction

This information is for you if you are starting, or have already started taking a medicine called ciclosporin. This page contains important information on how to take this medication safely.

For most medicines, information is provided by the manufacturer in the medicine package. However, this medicine does not have a license to be used for ulcerative colitis in the UK. This means that the information provided by the manufacturer does not tell you everything you need to know. This leaflet has been designed to provide you with some extra information.

Unlicensed use

Some medicines have been licensed for a certain condition and then later, experience or research shows that it works well for a different condition. The manufacturer can choose whether to apply to the Government to have more recent information added to the license. This is expensive and in some situations it is not economically viable to extend the license.

Ciclosporin is an immunosuppressant made by the manufacturer to prevent organ rejection after transplant and for the treatment of rheumatoid arthritis and psoriasis. However, it is also useful in the treatment of ulcerative colitis.

What is ciclosporin and how does it work?

Ciclosporin works by suppressing the immune system, which is overactive in ulcerative colitis. When used in a severe flare of ulcerative colitis that has not responded to standard treatment for inflammatory bowel disease, including steroids, it has been demonstrated to reduce the need for surgical operations to remove the large bowel (known as a colectomy). 

Before starting treatment

Before starting treatment with ciclosporin your doctor should check if you have any allergies, if you are (or could be) pregnant, or breast feeding. Receiving treatment with ciclosporin while you are pregnant could harm your unborn baby. If you are of child-bearing potential you should ensure that you use an effective form of birth control to prevent pregnancy. If you think you have become pregnant while using the medicine, tell your doctor right away. 

Your doctor should check if you have any pre-existing medical conditions that could be complicated by treatment or if you take any medicines that may interact. 

Conditions which you should ensure your doctor is aware of include:

  • Renal (kidney) or hepatic (liver) problems.
  • Poorly controlled high blood pressure.
  • Cancer.

What dose do I take?

The dose of ciclosporin is initially based on weight and may be adjusted according to the response and blood levels of the drug. Ciclosporin capsules are available as 10, 25, 50, or 100 mg strengths and you need to pay careful attention to the capsule strengths to achieve the correct dose. Ciclosporin is available in a liquid form if you have difficulty swallowing capsules. You should stay on the same brand of ciclosporin unless directed otherwise by your doctor.

How long will I take ciclosporin for?

Ciclosporin is usually a short-term (3-6 months) option as the risk of side effects increases with longer-term use. Most patients will be started on a medicine called a thiopurine (azathioprine or mercaptopurine) around the time of starting ciclosporin when there is evidence that symptoms are responding to ciclosporin treatment. The hope is that the thiopurine will take over from the ciclosporin and then keep the colitis in remission. You will receive information on this medicine if your consultant decides you need it. 

How should I take ciclosporin?

Some patients start ciclosporin intravenously (into the vein) when they are in hospital. If you respond well to the treatment, this is then changed to oral form (capsules or liquid) to take twice a day. Ideally the dose should be taken 12 hours apart. Capsules should be taken with water and swallowed whole. 

Grapefruit and grapefruit juice should be avoided as it can increase the ciclosporin levels in your blood.

How will I be monitored?

Regular blood tests will check the level of ciclosporin in the blood and also check that the kidneys and liver are working properly. These will be weekly initially, decreasing to fortnightly and then monthly once stable.

To measure the concentration of ciclosporin in the blood, the timing of the blood test is very important. We want to know the lowest drug level (drug trough level), which is 12 hours after your last dose, just before taking your next dose. Your ciclosporin drug level blood test should be planned for this trough level as best as possible. Your gastroenterology team at North Bristol NHS Trust will contact you if we need you to change your dose. 

Your blood pressure will be monitored regularly as ciclosporin may cause it to rise. These blood tests and blood pressure checks can be arranged with your GP surgery, and your GP will be informed of the monitoring you will need when you are on this medicine. The gastroenterology specialist pharmacists will be reviewing your blood results and will communicate any issues to you and your GP.

How will I get more prescriptions?

Ciclosporin can only be prescribed by a gastroenterology consultant or specialist registrar at North Bristol NHS Trust. 

The prescriber will ensure they provide you with enough medicine to last you until your next outpatient appointment. If you are running out of medications, or your dose changes and you require different strength capsules, contact the secretary for your consultant. Your GP will be informed that you are on this medication.

What are the common side effects?

The leaflet provided by the manufacturer for ciclosporin contains a list of all the effects reported for this medicine. It is very unlikely you will experience all the listed effects, but some of the most common side effects (occurring in more than 1 in 10 patients) are listed below:

  • Headache.
  • Increased hair growth.
  • Slightly enlarged or sore gums.
  • Shakiness of hands.
  • Feeling sick.
  • Reduced appetite.
  • Metallic taste in the mouth.
  • Cramps and painful periods – some women notice their periods cease whilst taking ciclosporin.

As ciclosporin suppresses the immune system, you are potentially at more risk of infections. If you develop a sore throat, any infections or begin to feel generally unwell contact your doctor, IBD nurse or pharmacist immediately.

What happens if I forget to take a dose? 

If you forget to take a dose, take another as soon as you remember, unless it is almost time for your next dose. Do not double dose. If you take too much tell your doctor immediately. 

Does ciclosporin interfere with other medication?

Ciclosporin can interact with other medications. Always tell your doctor that you are taking an immunosuppressant when any changes are made to your medication. You should also inform your dentist when you see them. Always check with your pharmacist before buying any over-the-counter medicines, alternative medicines or herbal remedies. Do not take aspirin or anti-inflammatory pain killers e.g. ibuprofen, unless prescribed by your doctor. 

Can I have vaccinations whilst I am taking ciclosporin?

You may not be able to have certain vaccinations whilst you are taking ciclosporin. All vaccinations may be less effective but live vaccines may also increase the risk of you developing the infection it’s protecting you from therefore should be avoided. Example of live vaccines are rotavirus, shingles, varicella, MMR (or any of the separate measles, mumps or rubella vaccines), yellow fever, oral typhoid and BCG. Discuss 
with your GP or IBD nurse before having any vaccinations.

For prescription queries please contact your consultants’ secretary or the gastro pharmacists/IBD nurses.

IBD advice line: 0117 4146354

Appointments helpline: 0300 5550103

© North Bristol NHS Trust. This edition published January 2024. Review due January 2027. NBT003124.

Hepatitis B Vaccination for people with Chronic Kidney Disease (CKD)

Regular Off Off

What is hepatitis B?

Hepatitis B is a serious inflammation of the liver that is caused by a viral infection.

It is spread by contact with blood and body fluids.

If you have long-term hepatitis B infection you can infect other people with the disease, even if you are well.

Around 1 in 5 people living with long-term hepatitis B will develop scarring of the liver. This happens over 10-20 years and is known as cirrhosis.

Why are people with chronic kidney disease at more risk of hepatitis B?

People with CKD are at an increased risk of hepatitis B infection because they are exposed to blood and body fluids during haemodialysis.

Some countries outside the UK have a higher rate of hepatitis B infection, so it is particularly important to be immunised if you plan to have haemodialysis abroad.

Procedures are in place to reduce the risk of hepatitis B infection across all sites supported by the Richard Bright Renal Unit, however the risk cannot be removed completely.

The Department of Health recommend that people with CKD are immunised against the hepatitis B virus. You won't have to pay for the vaccinations.

People who will need dialysis or may have a kidney transplant in the future are all offered immunisation.

People who have had a kidney transplant need to take medicines which dampen their immune system (immunosuppressive drugs). This makes it more difficult for their body to fight infection and can increase the risk of them developing a more severe hepatitis B infection.

The vaccine is safe for people on the kidney transplant waiting list.

Vaccination also prevents the disease spreading and causing harm to other people.

How is the vaccination Given?

The treatment involves a course of injections – which will be given in your upper arm, over a number of months. A nurse at your kidney unit clinic or haemodialysis unit will give you the injections.

The vaccination that will likely be given and the doses are described below, however there are other brands of vaccination available, so this may change. They will be given over a time period of six months.

Vaccination: HB VAX PRO 40®

  • Dose: 40mcg/ml
  • Total number of clinic visits: 3

Vaccination: ENERGIX B®

  • Dose: 40mcg/ml = 2 X 20mcg/ml per dose
  • Total number of clinic visits: 4

The doses of the vaccine used for people with chronic kidney disease are slightly higher than those used for people without kidney disease.

What happens when I have the vaccine?

The vaccination will encourage your body to produce antibodies to fight the hepatitis B virus – in case it  enters your blood stream. 

Your kidney doctor, pre-dialysis or dialysis nurse will arrange for you to have a blood test to measure your antibody level once you have completed the course of injections (2 months after you receive the 3rd dose).

For your protection, it is recommended that your antibody level is greater than 100mlU/ml. 

A level between 10 & 100 mlU/ml – will still give you some protection, but your doctor/nurse may recommend a further injection of the hepatitis B vaccine (a booster).

If you are on haemodialysis your hepatitis B antibody levels will be measured every year. If you level drops below 10mlU/ml you may be advised to have a booster injection.

For the immunisation to be most effective – it is very important that you have the injections at the recommended time and complete the course. Your doctor/nurse will remind you when your injections are due. We can provide you with a hepatitis B vaccination card if you wish.

Does the vaccine have any side-effects?

As with any vaccine, you may have a reaction or experience side-effects. These may include the following:

Common (about 1 in 10 people): 

  • Redness, tenderness, pain, and swelling at the injection site (this usually only lasts a few days).
  • Headache. 

Uncommon (about 1 in 100 people): 

  • Fever or flu-like symptoms.
  • Skin rash.

Very rare (less than 1 in 10,000 people):

  • Severe reaction: swelling of your face with difficulty breathing (anaphylactic reaction). 

Whoever gives you your vaccine will discuss possible side-effects with you. 

Who should not have the vaccine?

Before you have the first dose of the hepatitis B vaccine, please tell your doctor/nurse if you have had a severe reaction to any vaccine in the past.

If you have had a previous severe reaction to the hepatitis B vaccine you should not have another Hepatitis B vaccination.

If you have a high fever or severe infection when your vaccination is due, the vaccine should be given after you have recovered. If you have a minor infection e.g. cold – this should not be a problem with having the vaccination. You can discuss this with the nurse/doctor before you receive the jab.

There is no evidence of any risk from vaccinating pregnant or breastfeeding women against hepatitis B.

NHS Website: Hepatitis B - NHS (www.nhs.uk)

Please speak to your kidney doctor or renal nurse if you are unsure of anything or if you have any further questions or website: Renal (Kidney) | North Bristol NHS Trust (nbt.nhs.uk)

© North Bristol NHS Trust. This edition published February 2024. Review due February 2027. NBT002096. 

 

 

 

Dr Rachel Jayne Taylor - Emergency Medicine, Paediatric Emergency Medicine

Regular Off On A-Z of Consultants

GMC number: 7271871

Year & location of first qualification: Barts and the London, 2012

Specialty: Emergency Medicine, Paediatric Emergency Medicine

Clinical interests: Paediatric Emergency Medicine, Trauma, Education, Wellbeing

Secretary: Tina Allan

Secretary phone number: 0117 414 4112

Taylor

Dr James Matthams - Anaesthetics

Regular Off On A-Z of Consultants
Dr James Matthams

GMC number: 7293875

Year & location of first qualification: 2012, Imperial College London

Specialty: Anaesthetics

Clinical interests: General, regional anaesthesia, perioperative medicine

Secretary: Anaesthetic Department Secretary team

Secretary phone number: 0117 414 0976 

James Matthams is a fellow of the Royal College of Anaesthetists and was appointed a Consultant in Anaesthetics at North Bristol NHS Trust in 2023.

He regularly delivers general anaesthesia across a broad range of surgical specialities. He has developed subspeciality interests in regional anaesthesia and perioperative medicine.

Matthams